IBRX
ImmunityBio, Inc.
$8.22
-0.65 (-7.33%)
At close · Jul 10
Market Cap
$8.51B
Shares
1,047,353,977
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$113.29M
+668.3%
FY2025
Net Income
-$351.4M
+15%
FY2025
Gross Margin
99.34%
-0.7pp
FY2025
Operating Margin
-226%
+2108.2pp
FY2025
Diluted EPS
-$0.38
+38.7%
FY2025
Operating Cash Flow
-$304.94M
+22.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $140.98M | $113.29M | $14.75M | $622K | $240K | $934K | $605K | $2.2M | $47K | $45K | $44K | $236K | $641K | $600K | |
| $933K | $753K | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $140.04M | $112.54M | $14.75M | $622K | $240K | — | — | — | — | — | — | — | — | — | |
| — | 99.34% | 100% | 100% | 100% | — | — | — | — | — | — | — | — | — | |
| — | — | $190.14M | $232.37M | $248.15M | $195.96M | $139.51M | $112M | $55.72M | $42.04M | $29.15M | $11.43M | $1.6M | $446K | |
| — | — | $168.78M | $129.62M | $102.71M | $135.26M | $71.32M | $46.46M | $42.72M | $57.12M | $95.39M | $227.68M | $4.62M | $2.42M | |
| $2M | — | $2M | $2M | $1.9M | — | — | $600K | $2.3M | $2.3M | $2.6M | $1.3M | $0 | — | |
| — | $15.53M | $17.55M | $18.51M | $18.26M | $14.24M | $12.74M | $14.04M | $9.56M | $5.57M | $3.61M | $1.47M | $36K | $4000 | |
| — | — | $358.93M | $362.87M | $351.54M | $331.21M | $221.49M | $158.45M | $98.44M | $99.17M | $124.54M | $239.11M | $6.22M | — | |
| $402.37M | $369.32M | $358.93M | $362.87M | — | — | — | — | — | — | — | — | — | — | |
| -$261.39M | -$256.03M | -$344.18M | -$362.25M | -$351.3M | -$330.28M | -$220.88M | -$156.25M | -$98.39M | -$99.12M | -$124.5M | -$238.88M | -$5.58M | — | |
| — | -226% | -2334.23% | -58239.55% | -146374.17% | -35361.88% | -36509.09% | -7095.87% | -209338.3% | -220266.67% | -282954.55% | -101218.64% | -869.73% | — | |
| — | -$240.5M | -$326.63M | -$343.74M | -$333.04M | -$316.04M | -$208.14M | -$142.21M | -$88.83M | -$93.55M | -$120.89M | -$237.4M | -$5.54M | — | |
| — | $60.89M | $114.59M | $128.85M | $63.52M | $14.85M | $9.07M | $5.92M | — | $618K | $66K | $0 | $471K | $463K | |
| $1.25M | — | — | — | — | — | $1.23M | $1.64M | $2.32M | $4.23M | $5.17M | $312K | $20K | $2000 | |
| -$593.11M | -$95.58M | -$69.46M | -$221.64M | -$65.99M | -$19.56M | -$5.15M | -$4.01M | $1.66M | $2.2M | $3.12M | $1.7M | -$609K | — | |
| — | $0 | $0 | -$7.55M | -$12.11M | -$803K | $0 | $0 | — | $0 | $0 | -$56K | $0 | — | |
| $7.83M | $6.41M | $7.98M | $1.13M | -$3.09M | -$4.1M | $2.44M | $2.44M | — | — | — | — | — | — | |
| -$854.5M | -$351.61M | -$413.65M | -$583.89M | -$417.29M | -$349.84M | -$226.03M | -$160.26M | -$96.73M | -$96.92M | -$121.38M | -$237.18M | -$6.18M | — | |
| $108K | -$135K | $0 | -$40K | $34K | $9000 | -$1.85M | -$105K | -$503K | -$493K | -$572K | -$301K | $1000 | $1000 | |
| -$854.52M | -$351.4M | -$413.56M | -$583.2M | -$416.57M | -$346.79M | -$221.85M | -$157.78M | -$96.23M | -$96.42M | -$120.81M | -$236.88M | -$6.19M | -$2.05M | |
| — | -310.18% | -2804.77% | -93761.41% | -173569.58% | -37129.55% | -36669.59% | -7165.17% | -204736.17% | -214273.33% | -274565.91% | -100371.19% | -964.9% | -341.17% | |
| -$69K | -$74K | -$81K | -$656K | -$753K | -$3.06M | -$2.34M | -$2.38M | — | — | — | — | — | — | |
| -$854.53M | -$351.4M | -$413.56M | -$583.2M | -$416.57M | — | — | — | — | — | — | — | — | — | |
| -$847.04M | -$323.64M | -$412.38M | -$583.37M | -$416.39M | -$346.91M | -$92.4M | -$65.63M | -$96.11M | -$96.52M | -$120.9M | -$237.07M | -$6.19M | -$2.05M | |
| USD/shares | — | -$0.38 | -$0.59 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | — | — | — | — | — | — |
| USD/shares | — | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | — | — | — | — | — | — |
| shares | — | 919.86M | 697.31M | 508.64M | 399.9M | 389.23M | 377.07M | 366.32M | 79.13M | 80.58M | 81.98M | 71.52M | 8.25M | 797.11K |
| shares | — | 919.86M | 700.44M | 508.64M | 399.9M | 389.23M | 377.07M | 366.32M | 79.13M | 80.58M | 81.98M | 71.52M | 8.25M | 797.11K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2021: $38.6M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $113,288,000 | $14,745,000 | $622,000 | $240,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| United States | $113,010,000 | $14,214,000 | $31,000 | $42,000 | $373,000 | $513,000 | $1,997,000 |
| Europe | $278,000 | $531,000 | $591,000 | $198,000 | $561,000 | $92,000 | $205,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Product | $112,982,000 | $14,150,000 | $0 | $0 |
| Product And Service Other | $306,000 | $595,000 | $622,000 | $240,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | -$256,027,000 | -$344,182,000 | -$362,250,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | -226% | -2334.2% | -58239.5% |
Key facts
CIK
1326110
CUSIP
45256X103
13F (30d)
18 filings
18 filers
Visit website
Investor relations